News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Two Phase III Studies of Genentech (South SF) (DNA)'s Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion



10/5/2009 8:53:30 AM

GENEVA--(BUSINESS WIRE)--The Swiss company Sensometrix SA, a new player in the world of biometrics, introduces two unique products at the cutting edge of the authentication domain. A new era is opening in the field of security and access control thanks to the SensoBrain technology, an algorithm which guarantees fast response time and optimum security standards despite large, or even very large, databases.

Read at BioSpace.com


comments powered by Disqus
Genentech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES